Related Experiment Videos
Solitary bone and extramedullary plasmacytoma
1University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 001, Houston, TX 77030, USA. dmweber@mdanderson.org
Hematology. American Society of Hematology. Education Program
|November 24, 2005
Summary
A small percentage of plasma cell dyscrasia patients have solitary bone (SBP) or extramedullary plasmacytoma (EMP). Radiotherapy offers long-term disease-free survival for these localized plasma cell disorders.
Area of Science:
- Hematology
- Oncology
- Radiotherapy
Background:
- Plasma cell dyscrasias are a group of disorders characterized by the proliferation of monoclonal plasma cells.
- Less than 5% of patients present with solitary bone plasmacytoma (SBP) or extramedullary plasmacytoma (EMP) without systemic disease indicators.
Purpose of the Study:
- To outline the diagnostic criteria and treatment outcomes for SBP and EMP.
- To highlight the efficacy of radiotherapy in managing these localized plasma cell neoplasms.
Main Methods:
- Diagnosis involves biopsy confirmation of a monoclonal plasma cell infiltrate from a single site.
- Treatment of choice is curative-intent radiotherapy (> 4000 cGy).
Main Results:
- Long-term disease-free survival rates were approximately 30% for SBP.
- Long-term disease-free survival rates were approximately 65% for EMP.
Conclusions:
- SBP and EMP are rare presentations of plasma cell dyscrasias.
- Radiotherapy is an effective treatment modality for achieving long-term remission in SBP and EMP.